Aeon biopharma reports fourth quarter and full year 2023 financial results

– recent end-of-phase 2 meeting with fda resulted in alignment on the design and endpoints for the proposed pivotal phase 3 trials for the preventive treatment of both episodic and chronic migraine –

AEON Ratings Summary

AEON Quant Ranking